A new species of the genus Spinoctenus Hazzi, Polotow, Brescovit, González-Obando et Simó, 2018 (Araneae: Ctenidae) from Panama

Posted by
  A new species of the genus Spinoctenus Hazzi, Polotow, Brescovit, González-Obando et Simó, 2018 (Araneae: Ctenidae) from Panama A new species Spinoctenus leleji sp. n . is described from Panama based on a male specimen. This is the first record of the genus Spinoctenus from Panama and the second record of this genus outside South America. The new species is most similar to S. tequendama Hazzi, Polotow, Brecovit, González-Obando et Simó, 2018, but differs by the structure of the male palp and the shape of metatarsus IV. Photographs of the habitus and copulatory organs are provided. The type locality of the new species is mapped. Omelko, Мichail M. 2026. A new species of the genus Spinoctenus Hazzi, Polotow, Brescovit, González-Obando et Simó, 2018 (Araneae: Ctenidae) from Panama. Far Eastern Entomologist(554): 19-24.  https://biosoil.ru/fee/publication/2988

Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis

Posted by

 


Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis

Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by tissue infiltration of MCs driving clinical symptoms.1 The disorder is characterized by activating mutations in the KIT protein, classically KIT p.D816V. SM is treated in a symptom-guided manner with therapies targeted toward bioactive MC mediators. However, the recent discoveries of targeted tyrosine kinase inhibitors have changed the treatment paradigm of indolent SM (ISM).2 Tyrosine kinase inhibitors have demonstrated to reduce MC burden and improve quality of life. To date, they have not been used to facilitate venom immunotherapy (VIT). Patients with mastocytosis and Hymenoptera venom allergy may have recurrent anaphylaxis during VIT, and adjunctive therapies are a significant unmet need to protect this patient population. Although omalizumab has been found to be effective in a subset of patients, non-IgE-mediated mechanisms may be activated by Hymenoptera venom and an increased mutated MC burden may contribute to life-threatening symptoms. We report, here, the first case of successful VIT in a patient with ISM treated with avapritinib.

Depina, L., Karmarkar, S. N., Moeller, S., Lazarovich, M., De Magalhães, A. R., Castells, M., & Giannetti, M. P. (2025). Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis. Annals of Allergy, Asthma & Immunology, 135(3), 343-344. https://doi.org/10.1016/j.anai.2025.06.015